FirstIgnite is supporting the commercialization of the University of Utah’s novel synthetic pathway technology. This technology is a novel synthetic approach to producing a wide range of synthetic VLC-PUFAs in relatively large quantities for research and high-quality dietary supplements. Furthermore, this technology can be produced without heavy metals for safety and non-toxicity, its mouse studies indicate high oral bioavailability for retinal tissue, and supplementation may reduce retinal degeneration in patients with age-related macular degeneration (AMD) and Stargardt-3 disease.This technology is applicable to therapeutics, ophthalmology, and nutrition/supplements. As of 2022, the global ophthalmic drugs market is worth $35.8 billion and is expected to reach $65.6 billion by 2030.The University of Utah’s novel synthetic pathway technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the University of Utah team, you can schedule a time directly on their team’s calendar here.